Andy Hsieh
Stock Analyst at William Blair
(3.08)
# 1,221
Out of 5,138 analysts
11
Total ratings
83.33%
Success rate
66.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Initiates: Outperform | n/a | $15.37 | - | 1 | Dec 12, 2025 | |
| TERN Terns Pharmaceuticals | Upgrades: Outperform | n/a | $36.60 | - | 2 | Nov 3, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $8.32 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $1.00 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $4.24 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $88.64 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $20.16 | - | 1 | Feb 28, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.76 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $64.25 | - | 1 | Sep 29, 2023 | |
| ATNM Actinium Pharmaceuticals | Downgrades: Market Perform | n/a | $1.33 | - | 1 | Feb 21, 2023 |
Aardvark Therapeutics
Dec 12, 2025
Initiates: Outperform
Price Target: n/a
Current: $15.37
Upside: -
Terns Pharmaceuticals
Nov 3, 2025
Upgrades: Outperform
Price Target: n/a
Current: $36.60
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.32
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.00
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.24
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $88.64
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $20.16
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $64.25
Upside: -
Actinium Pharmaceuticals
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -